Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cell Therapeutics adds three members to advisory board

This article was originally published in Scrip

Biopharmaceutical company Cell Therapeutics has appointed Alan List, Ross Levine and Brian Druker to its recently formed scientific advisory board. All three newly named members have expertise in blood cancer research and development. Dr List is president and CEO of Moffitt Cancer Center and a professor of internal medicine and oncology at the University of South Florida College of Medicine; Dr Levine is associate attending physician at Memorial Sloan-Kettering Cancer Center; and Dr Druker is director of the Knight Cancer Institute at Oregon Health and Science University (OHSU), chair of Leukemia Research at OHSU, and an Investigator of the Howard Hughes Medical Institute. The advisory board will advise on the development of Cell's oncology programs and evaluate new opportunities in the treatment of blood-related cancers.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC023090

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel